A Phase I, Multi-Centre, Open-Label, Dose Selection Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Etoposide and Cisplatin (EP) as First Line Therapy for Lung Cancer Patients With Extensive Stage or Metastatic Disease for Whom EP Would be a Standard Therapy
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171) in combination with etoposide and cisplatin (EP).
From date of consent through to data cut-off, 7th August 2009.
John Heymach, MD
M.D. Anderson Cancer Center
United States: Food and Drug Administration
|Research Site||Anaheim, California|
|Research Site||Boulder, Colorado|
|Research Site||Hays, Kansas|
|Research Site||Abilene, Texas|